BMO Capital Markets initiated coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research note released on Tuesday morning. The brokerage issued an outperform rating and a $35.00 price objective on the biotechnology company’s stock.

Several other equities analysts also recently commented on the stock. Bank of America reissued a buy rating and issued a $33.00 target price (up previously from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. Zacks Investment Research downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a report on Wednesday, October 11th. Leerink Swann reissued an outperform rating and issued a $29.00 target price (up previously from $22.00) on shares of Audentes Therapeutics in a report on Wednesday, November 15th. Raymond James Financial initiated coverage on shares of Audentes Therapeutics in a report on Thursday, October 12th. They issued a market perform rating on the stock. Finally, ValuEngine downgraded shares of Audentes Therapeutics from a hold rating to a sell rating in a report on Friday, October 13th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $28.29.

Shares of Audentes Therapeutics (BOLD) traded down $0.29 during trading hours on Tuesday, reaching $27.38. 130,700 shares of the company’s stock traded hands, compared to its average volume of 148,087. Audentes Therapeutics has a twelve month low of $13.90 and a twelve month high of $33.43.

Audentes Therapeutics (NASDAQ:BOLD) last issued its quarterly earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, meeting the consensus estimate of ($0.88). equities research analysts forecast that Audentes Therapeutics will post -3.52 EPS for the current fiscal year.

In related news, CEO Matthew R. Patterson sold 10,000 shares of the business’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $25.06, for a total value of $250,600.00. Following the sale, the chief executive officer now owns 1,542 shares in the company, valued at $38,642.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP David Nagler sold 3,750 shares of the business’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $25.00, for a total transaction of $93,750.00. Following the completion of the sale, the senior vice president now owns 3,750 shares in the company, valued at approximately $93,750. The disclosure for this sale can be found here. Insiders sold 766,500 shares of company stock worth $21,568,850 in the last 90 days. 47.30% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Redmile Group LLC increased its position in Audentes Therapeutics by 77.8% during the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after acquiring an additional 638,780 shares during the last quarter. Jennison Associates LLC increased its position in Audentes Therapeutics by 182.4% during the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock valued at $16,189,000 after acquiring an additional 546,617 shares during the last quarter. Perceptive Advisors LLC increased its position in Audentes Therapeutics by 10.4% during the third quarter. Perceptive Advisors LLC now owns 781,309 shares of the biotechnology company’s stock valued at $21,885,000 after acquiring an additional 73,809 shares during the last quarter. Vanguard Group Inc. increased its position in Audentes Therapeutics by 130.3% during the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after acquiring an additional 383,837 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of Audentes Therapeutics by 31.5% in the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock worth $12,256,000 after purchasing an additional 153,617 shares during the last quarter. Institutional investors own 78.99% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/audentes-therapeutics-bold-coverage-initiated-by-analysts-at-bmo-capital-markets/1747913.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.